Invasion and metastasis are the major features of malignant tumors that are responsible for 90% of cancer-related deaths. Recently, microRNAs have been discovered to have a role in suppressing tumor metastasis. This study's aim was to clarify the roles of miR-145 in gastric carcinomas and its underlying molecular mechanism in regulating tumor metastasis. Here, we demonstrate a stepwise downregulation of miR-145 level in nontumorous gastric mucosa, primary gastric cancers and their secondary metastases. In vitro analysis of miR-145's ectopic expression and loss-of-function suggests that it suppresses gastric cancer cell migration and invasion. In vivo spontaneous metastasis and experimental metastasis assay further confirm its function in suppressing the invasion --metastasis cascade, including impairing local invasion and inhibiting hematogenous metastasis in gastric cancers. Furthermore, we identified a novel mechanism of miR-145 to suppress metastasis. N-cadherin (CDH2) was proved to be a direct target of miR-145, using luciferase assay and western blot. Re-expressing N-cadherin in miR-145-transfected cells reverses their migration and invasion defects. Although not a direct target of miR-145, matrix metallopeptidase 9 (MMP9), but not MMP2, was also significantly decreased in miR-145-expressing cells. We suggest that miR-145 suppresses tumor metastasis by inhibiting N-cadherin protein translation, and then indirectly downregulates its downstream effector MMP9.
INTRODUCTION
Invasion and metastasis are the major features of malignant tumors that are responsible for 90% of cancer-related deaths. 1 Metastasis is a process that encompasses multiple steps, including cell motility, adjacent tissue invasion, intravasation, dissemination through the vasculature and finally proliferation from micrometastasis to macroscopic secondary tumor. 2 Investigations on genes and gene products that drive the process have been carried out, but the molecular pathways underlying the process are still obscure. Accumulating evidence suggests that in addition to genetic alterations, non-coding RNAs, especially microRNAs (miRNAs), also contribute to cancer pathogenesis. 3 miRNAs contain 20 to 25 nucleotides, and can lead to the suppression of their target genes by binding messenger RNAs at their 3 0 -untranslated regions (3 0 -UTRs), thereby either inhibiting their translation or occasionally causing their cleavage. 4 Recently, it has been discovered that miRNAs have a role in tumor metastasis. 5, 6 In metastasis-positive breast cancers, miR-10b is activated by the transcription factor TWIST1, 7 and initiates invasion and metastasis by direct downregulation of homeoboxD10 (HOXD10). miR-21 was found to initiate the tumors' ability to metastasize by direct repression of the phosphatase and tensin homolog (PTEN) 8 and two matrix metallopeptidase (MMP) inhibitors, reversion-inducing cysteine-rich protein with kazal motifs (RECK) and TIMP metallopeptidase inhibitor 3 (TIMP3). 9 On the other hand, miR-126 was found to inhibit cell migration and invasion partially through suppression of v-crk sarcoma virus CT10 oncogene homolog (CRK), a signal protein associated with focal adhesion formation and cell migration in lung cancers. 10 miR-206 also demonstrated the capacity to suppress the metastatic ability of cancer cells by directly repressing Notch 3.
11
However, all these various miRNAs including pro-metastatic (miR-10b, miR-21 and miR-373/520c) and anti-metastatic (miR-126 and miR-206) exert confounding influences on tumor growth at the meantime. 7 --11 The specific contributions of miRNAs in the processes of metastasis, independent of cell growth, are not clearly understood.
Moreover, it is reported that the roles of miRNAs in cancer are tissue-or cell-specific. For example, miR-155 is highly downregulated in endocrine tumors, whereas in lymphomas it is overexpressed. 4 miR-145 is underexpressed in breast, colon and bladder cancers. 12 --15 However, there is a controversy regarding miR-145's ability to suppress tumor invasion. miR-145 was reported to suppress cell invasion and metastasis by directly targeting mucin 1 (MUC1) in breast cancers. 12 In contrast, Valastyan et al. 16 showed that miR-145 failed to influence invasion or motility in metastatic MDA-MB-231 breast cancer cells. These researchers even used miR-145 as a negative control for miR-31. The latter was proved to be an anti-metastasis miRNA by targeting ras homolog gene family A (RHOA), a metastasis-promoting gene. 16 In gastric cancers, Takagi et al. 17 showed that miR-145 was generally downregulated, and that overexpression of miR-145 suppressed cell growth in human cancer cell line. However, the roles of miR-145 in the progression of gastric carcinoma and its underlying molecular ability to regulate tumor metastasis remain elusive. Here, we identify a novel mechanism of miR-145 to suppress the invasion --metastasis cascade in gastric cancer by directly targeting N-cadherin protein translation and then indirectly downregulating its downstream effector MMP9, without affecting tumor growth.
RESULTS miR-145 expression is under-regulated in human gastric cancers and gastric cancer cell lines Compared with human nontumorous gastric mucosa, miR-145 in gastric cancers was found to be significantly underexpressed. A further downregulation of miR-145 was observed in the loci of secondary metastases compared with primary gastric cancers (Figure 1a , analysis of variance, P ¼ 0.022). Expression of miR-145 was also assayed in four human gastric cancer cell lines. Compared with human nontumorous gastric mucosa, miR-145 was decreased in all four cell lines. This was especially so in SGC-7901 cells, which are capable of metastasizing and showed a 2-to 31-fold lower miR-145 expression than the other three nonmetastatic cell lines (Figure 1b) . Furthermore, miR-145 levels were proven, by spontaneous metastasis assay in vivo, to be downregulated in lung metastases compared with primary xenograft tumors from which they were derived ( Figure 1c , t-test, P ¼ 0.015). Thus, the level of miR-145 is specifically attenuated in aggressive human gastric cancer tissues and cell lines.
miR-145 suppresses cell migration and invasion of gastric cancer cell lines in vitro Noting the inverse correlation between miR-145 level and metastasis, we expressed miR-145 in gastric cancer cells BGC-823 and SGC-7901. Transfection of miR-145 precursor resulted in significant overexpression of miR-145 (Figure 2a , t-test, Po0.001). As expected, ectopic expression of miR-145 significantly suppressed cell migration and invasion ability (Figure 2b , t-test, P ¼ 0.027 and 0.036, respectively), whereas overexpression of the miR-negative control failed to influence cell migration and invasion compared with non-transfected cells.
We then performed in vitro loss-of-function analyses by silencing miR-145 with anti-miR-145 inhibitor (Figure 2c , t-test, P ¼ 0.013). The results showed that the anti-miR-145 inhibitor rather than the negative inhibitor control enhanced cell migration and invasion in both BGC-823 and SGC-7901 cells (Figure 2d , t-test, P ¼ 0.038 and 0.031, respectively). Hence, miR-145 may have a suppressive role in cancer cell migration and invasion in vitro.
miR-145 suppresses invasion and metastasis in vivo
To address whether miR-145 could suppress invasion and metastasis in vivo, SGC-7901 cells expressing ectopic miR-145 were implanted in left axillary fossa of mice to form ectopic tumors. In this study, lentivirus miR-145-expressing vector pEZXmiR145 could stably express miR-145 (Supplementary Figure 1) and green fluorescent protein (GFP) for at least 8 weeks in vitro. It could also be stably expressed in implanted tumor nodules in vivo, with GFP expression clearly observed in living mice by Kodak 2000 imager (Kodak, Rochester, NY, USA) throughout the whole experimental period (Figure 3a) . The xenograft tumors of miR-145-transfected groups had significantly higher miR-145 levels than the pEZX-miR-negative control group (Supplementary Figure  2) . We found that the pEZX-miR-negative control group displayed local invasion around the tumors, with islands of cancer cells invading the stroma or muscle tissues (Figures 3b and c) . However, the tumors with miR-145-expressing cells were noninvasive or well-encapsulated, as shown by their intact fibrotic capsules (Figures 3d and e) . Moreover, miR-145 impaired the tumor's capacity to seed lung metastases. Six weeks after implantation, clusters of GFP-positive cells were observed in frozen lung sections of the miR-negative control group by fluorescent microscopy ( Figure 3f ). The cells were confirmed as metastatic cancer cells in hematoxylin and eosin (H&E) sections (Figure 3g ) and found positive for carcinoembryonic antigen (CEA) immunostaining (Figure 3h ). In contrast, no metastasis was found in any of the five mice of the miR-145-expressing group. As stromal invasion is an important process, which occurs before distant metastasis, these data suggest that miR-145 suppresses metastasis of ectopic tumors, due at least in part to its ability to impair local invasion.
Furthermore, we injected miR-145-expressing cells directly into the tail vein of mice. Six weeks afterward, miR-145-expressing cells developed 71.3 ± 6.2% fewer lung micrometastases than the control (Figure 4a , t-test, P ¼ 0.021). The micrometastases were GFP-positive (Figure 4b ). H&E-stained sections further revealed the malignant morphologic phenotype (Figure 4c ) of cancer cells, which also showed positive immunostaining for CEA (Figure 4d) . Thus, the results indicate that miR-145 represses the invasion --metastasis cascade from local invasion to hematogenous metastasis. Figure 3) . Moreover, the Edu DNA proliferation assay also showed that miR-145 had no significant effect on cell Figure 1 . miR-145 level is specifically attenuated in aggressive human gastric cancer tissues and cell lines. (a) miRNA was extracted using miRNeasy FFPE kit (Qiagen) from 136 cases of primary gastric cancer tissues, 64 cases of secondary metastasis cancer loci and 27 cases of nontumorous gastric mucosa. Quantitation of miR-145 expression levels was performed using RT --qPCR (analysis of variance, P ¼ 0.022). (b) RNA in cell lines was extracted using Trizol reagent (Invitrogen). Quantitation of miR-145 expression levels was performed using RT --qPCR. miR-145 was especially underexpressed in SGC-7901 cells, which are capable of metastasizing and showed a 2-to 31-fold lower miR-145 expression than the other three nonmetastatic cell lines (t-test, Po0.001). (c) RNA in mice primary xenograft tumors and lung metastases was extracted using miRNeasy FFPE kit (Qiagen). miR-145 expression levels were determined by RT --qPCR (t-test, P ¼ 0.015, n ¼ 5). miR-145 directly regulates N-cadherin in gastric cancer cells To understand how miR-145 suppresses tumor invasion and metastasis, we used three algorithms (Targetscan, Pictar and Miranda) to help identify miR-145 targets in human gastric cancers. Among hundreds of target genes predicted to be regulated by miR-145, two putative targets ((N-cadherin and hepatocyte growth factor) that have been implicated in tumor invasion or metastasis, and reported to be overexpressed in human tumors were selected. 18 --20 We cloned 3 0 -UTRs of the targets into a luciferase construct pmirGLO. Finally, N-cadherin was identified as a direct target of miR-145. The 3 0 -UTR element of N-cadherin messenger RNA is partially complementary to miR-145 ( Figure 6a ). The luciferase assay revealed that miR-145 significantly ) were resuspended in serum-free medium and seeded to the upper chamber of Transwell inserts, with culture medium containing 10% fetal bovine serum added to the lower chamber. The migrated cells were fixed, stained and counted 24 h later. For invasion assay, the experiment was done using membranes coated with Matrigel matrix (BD Science). Each experiment was performed in duplicate (t-test, P ¼ 0.027 and 0.036, respectively). (c and d) The cells were transfected with 30 nM of antimiR-145 inhibitor or the negative control, with the other performance same as above. Anti-miR-145 inhibitor could decrease miR-145 level (c, t-test, P ¼ 0.013) and enhance cell migration and invasion in both BGC-823 and SGC-7901 cells (d, t-test, P ¼ 0.038 and 0.031, respectively). Each experiment was performed in duplicate independently.
reduced the activity of the luciferase reporter gene fused to the N-cadherin 3 0 -UTR by 46.5 ± 12.6% and 51.6 ± 15.8% in BGC-823 and SGC-7901 cells, respectively, compared with the miR-negative control (Figure 6a , t-test, P ¼ 0.026). Mutation of the putative miR-145 sites in the 3 0 -UTR of N-cadherin abrogated luciferase responsiveness to miR-145 (t-test, P ¼ 0.636). Western blot showed that N-cadherin protein levels were suppressed by 56.2±11.5% and 63.8 ± 17.2% in miR-145-expressing BGC-823 and SGC-7901 cells, respectively (Figure 6b ). IHC also confirmed the downregulation of N-cadherin protein expression in miR-145-expressing cells (Figure 6c ). Moreover, western blot analysis of implanted tumors in mice proves that N-cadherin protein was significantly downregulated in the miR-145-transfected group, compared with the miR-negative control group (Figure 6d ). E-cadherin, another member of the cadherin family, was not affected by miR-145 transfection (Supplementary Figure 5) .
We further extended our investigation in human gastric cancer samples. N-cadherin protein (Figures 6e --g ) tends to be elevated in samples with low miR-145 expression. An inverse correlation was found between miR-145 level and N-cadherin protein expression (Figure 6h, linear correlation, P ¼ 0.009, r ¼ À0.527). These data further corroborate that N-cadherin is the direct target gene of miR-145 in human gastric cancers.
Re-expression of N-cadherin promotes invasion To understand whether the reduced-invasion phenotypes associated with miR-145 could be reversed via restoration of N-cadherin expression, N-cadherin was re-expressed in miR-145-transfected SGC-7901 cells. In miR-145-expressing cells, the presence of N-cadherin reversed their migration and invasion defects (Figure 7a , t-test, P ¼ 0.033 and 0.026, respectively). In contrast, inhibition of miR-145 expression by anti-miR-145 inhibitor caused increased levels of N-cadherin (Figure 7b ) and subsequent active migration or invasion ability (Figure 2d ). Transfection with small interfering RNA (siRNA) N-cadherin targets into these anti-miR-145 inhibitor transfected cells resulted in N-cadherin downregulation (Figure 7c ) and reduced migration and invasion activity (Figure 7d , t-test, P ¼ 0.035 and 0.029, respectively).
Furthermore, we found significantly increased MMP9 protein levels in both cells transfected with anti-miR-145 inhibitor or N-cadherin, whereas the cells treated with siRNA showed reduced MMP9 expression (Figure 7e ) and activity (Supplementary Figure  6) . As MMP9 is not a direct target of miR-145 (Figure 7f , t-test, P ¼ 0.436), we believe miR-145 may regulate MMP9 expression in an indirect way, for example, through regulation of N-cadherin expression. MMP2, another member of MMPs family, was not found to be deregulated by miR-145 transfection (Supplementary Figure 7) . Moreover, MMP-9 siRNA could suppress MMP-9 expression or activity and block N-cadherin-induced invasion (Supplementary Figure 8) . These data indicate that MMP-9 may serve as a downstream effector of miR-145 through which it may suppress gastric invasion. DISCUSSION miRNAs serve as master regulators of gene expression in a sequence-specific fashion. Those miRNAs that are underexpressed in tumors may be tumor suppressors, and generally participate in oncogene overexpression. 21 miR-145 was reported to be underexpressed in breast (2.5-fold), colon (5-fold) and bladder cancers (20-fold).
12 --14 Our previous study found that miR-145 was downregulated in precancerous and early liver cancers, suggesting its possible role in tumor carcinogenesis. 22 In this study, the miR-145 expression level was lower by 32.35-fold in gastric cancer tissues compared with corresponding nontumorous tissues.
We are particularly interested in miR-145's ability to suppress tumor metastasis. In the present study, we showed a stepwise downregulation of miR-145 in nontumorous gastric mucosa, primary gastric cancers and their secondary metastases. Moreover, compared with nontumorous gastric mucosa, miR-145 was significantly underexpressed in gastric cancer cell lines. This was especially true of the metastatic SGC-7901 cell line. Furthermore, ectopic expression and loss-of-function analysis of miR-145 in vitro suggest that miR-145 is able to suppress migration and invasion, and may serve as a metastasis-suppressor gene. Spontaneous and experimental metastasis assays in vivo further corroborated its function in suppressing the invasion --metastasis cascade, including impairing local invasion and inhibiting hematogenous metastasis in gastric cancers.
Evidence of miR-145 as a tumor growth inhibitor has been reported in gastric cancers, 17 colon cancers 15 and B-cell lymphoma cell lines. 23 In breast cancer, miR-145 seems to inhibit cell growth in a cell-specific manner. For example, it could suppress cell growth only in MCF-7 cells, but not in other cell lines such as MDA-MB-231 and LM2-4142. 12 In this study, we demonstrated that miR-145 had no effect on cell growth or cell proliferation of four gastric cancer cell lines BGC-823, SGC-7901, MKN-45 and MKN-28. Moreover, Spearman's correlation test showed that there was no correlation between miR-145 expression levels and tumor size in human gastric cancer samples. Our results indicate that miR-145 could not always serve as a growth inhibitor in gastric cancers. Takagi et al. reported that miR-145 could suppress cell growth ingastric cancer cell MKN-1 and KATO III. We also observed the same inhibitory function of miR-145 in liver cancer cells Hep G2 and Hep 3B. 22 We believe that the discrepancy between our results in gastric cancers and that of others is because the roles that miRNAs have are tissue-or cell-specific. 4 At present, most miRNAs that have been reported to initiate or repress tumor metastasis could also influence cell growth. 7 --9,11,24 Cell growth may also have an effect on the process of metastasis, for example by taking part in the final step of metastasis colonization. We believe that in gastric cancers, miR-145 may suppress tumor metastasis in a way independent of affecting cell proliferation.
Then we addressed the molecular mechanism of miR-145 in suppressing metastasis in gastric cancer cells. In this study, the luciferase assay and western blot showed that N-cadherin is a direct target of miR-145. This conclusion was further confirmed in mice xenograft tumors and human gastric cancer samples. A significant inverse correlation between miR-145 and N-cadherin expression was found in both kinds of samples. N-cadherin is a calcium-dependent cell adhesion molecule that is associated with an increased invasive potential. 25, 26 We also showed that when miR-145-expressing cells re-expressed N-cadherin, their invasion defects were reversed, whereas using a miR-145 inhibitor to inhibit miR-145 resulted in N-cadherin upregulation. And when the upregulation of N-cadherin was further silenced by siRNA targets to N-cadherin, the migration and invasive activity of the treated cells was repressed accordingly. Therefore, we believe that miR-145 has a role in the suppression of metastasis in gastric cancers by downregulating N-cadherin protein expression.
Interestingly, MMP9, an extracellular matrix-degrading enzyme, was also significantly decreased in miR-145-transfected cells. However, luciferase assay showed that MMP9 is not a direct target of mir-145. MMP9 has been reported to be directly involved in cancer metastasis, 27 and an increase of MMP9 may endow cancer cells with a greater ability to penetrate matrix barriers and directly promote cancer invasion.
28 MMP9 activity could be upregulated by N-cadherin.
29, 30 We also observed that MMP9 expression could be up-or downregulated in N-cadherin-transfected cells or N-cadherin-silencing cells. Our results suggest that MMP9 may be a downstream effector of miR-145; the latter seems to downregulate MMP9 expression indirectly by targeting N-cadherin and then suppressing the ability of cancer cells to penetrate matrix. The expression level of MMP-2, another member of MMPs family, was not altered in N-cadherin siRNA-transfected cells, suggesting MMP-2 was not a downstream effector of N-cadherin. In fact, Hartland et al. 31 found that MMP-2 could directly cleave N-cadherin and induce cell apoptosis.
All together, the present study demonstrates that miR-145 has a suppressive role in the invasion --metastasis cascade but not in the tumor growth process in gastric cancers. We identified a novel mechanism of miR-145 to suppress metastasis. Our results suggest that miR-145 suppresses tumor metastasis by inhibiting the protein translation of its direct target gene N-cadherin, and then may indirectly downregulate its downstream effector MMP9. The feature of miR-145 as tumor suppressor indicates it to be a novel therapeutic target for cancer therapy. It would be interesting to explore whether miR-145 may serve as a therapeutic agent for patients with gastric cancers.
MATERIALS AND METHODS Patients
Gastric cancer tissues were obtained from 136 patients who underwent gastrectomy with lymph node dissection at Qi Lu Hospital of Shandong University from 2004 to 2005. Among them, 64 cases were proven to include lymphatic metastasis, determined by pathology examination. Another 27 samples of nontumorous gastric mucosa more than 3 cm away from tumors were used as nontumorous controls. The study was approved by the Ethics Committee of Shandong University. All specimens were collected and embedded in paraffin for histological diagnosis and immuno study. Specimens were typed histologically according to Lauren's and the World Health Organization (WHO)'s classifications (IARC Press, Lyon, 2000). Clinicopathological characters included in this study are summarized in Supplementary Table 1. RNA extraction Paraffin sections 4 mm thick were cut, dewaxed, rehydrated and lightly stained with hematoxylin. Tumor tissues were examined and microdissected under a dissecting microscope (Leica ASLMD, Witts Baden, Germany). miRNA extraction was performed with a miRNeasy FFPE kit (Qiagen, Valencia, CA, USA), which enables copurification of total RNA, including miRNA, from formalin-fixed paraffin-embedded tissue sections. For cell lines, total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA).
Real-time quantitation of miRNA expression levels using RT --qPCR miRNA expression levels were quantitated using a MicroRNA Assay Kit (Applied Biosystem, Foster City, CA, USA) according to the manufacturer's instructions. Briefly, a two-step protocol involves reverse transcription with a miRNA-specific primer to convert miRNA to complementary DNA, followed by real-time quantitative PCR (RT --qPCR) with TaqMan probes. All reactions were run in duplicate. The universal small nuclear RNA U6 (RNU6B) was used as an endogenous control for miRNAs. 
Cell proliferation assay
Cells were counted with a particle counter (Beckman Coulter, Munich, Bavaria, Germany) 24, 48 and 72 h after transfection. Each experiment was performed in triplicate. Figure 7 . Re-expression of N-cadherin promotes invasion. (a) N-cadherin was transfected in miR-145-expressing SGC-7901 cells using X-tremeGENE (Roche Applied Science). Then cell migration or invasion assay was performed using Transwell inserts coated with or without Matrigel matrix (t-test, P ¼ 0.033 and 0.026, respectively). (b) The SGC-7901 cells were transfected with anti-miR-145 inhibitor or anti-miRnegative control using X-tremeGENE (Roche Applied Science). Then N-cadherin protein was detected by western blot (t-test, P ¼ 0.029). (c and d) siRNA targets N-cadherin was transfected into these miR-145-knockout cells. Then N-cadherin protein was detected by western blot (c, t-test, P ¼ 0.015). Cell migration or invasion assay was performed using Transwell inserts coated with or without Matrigel matrix (d, t-test, P ¼ 0.031 and 0.0226, respectively). (e) Western blot was performed with antibodies against MMP9 (1:1000, Abcam), with significantly increased MMP9 levels observed in both cells transfected with anti-miR-145 inhibitor (e, left, P ¼ 0.036) or N-cadherin (e, middle, P ¼ 0.032), whereas the N-cadherin-downregulated cells treated with siRNA showed reduced MMP9 expression (e, right, P ¼ 0.043). (f ) Luciferase assay shows that MMP9 is not a direct target of miR-145 (t-test, P ¼ 0.436). Renilla and firefly luciferase activities were measured with the Dual-Luciferase Reporter system (Promega) 24 h after transfection. Firefly luciferase activity was normalized to Renilla luciferase expression for each sample. Each experiment was performed in triplicate.
Cell migration and invasion assay
The migration assay was performed with Transwell inserts that have 6.5-mm polycarbonate membranes with pores 8.0 mm in size (Corning, New York, NY, USA). Matrigel invasion assay was done using membranes coated with Matrigel matrix (BD Science, Sparks, MD, USA). The cells (1 Â 10 5 ) were resuspended in serum-free medium and seeded to the upper chamber. Culture medium containing 10% fetal bovine serum was added to the lower chamber. The cells were incubated in a humidified incubator at 37 1C for 24 h. The migrated cells were fixed, stained and counted. Each experiment was performed in duplicate.
Plasmid construction
The 3 0 -UTR sequence of target genes carrying a putative mir-145 binding site was amplified by PCR using primers (shown in Supplementary Table 2) and confirmed by DNA sequencing. A mutant miR-145 expression vector was used as a negative control as described previously. 12 To generate a mutant N-cad-3 0 -UTR, we adopted the two-step PCR method as reported previously. 32 Briefly, two fragments of N-cad-3 0 -UTR were amplified by two sets of overlapped primers (shown in Supplementary Table 2 ) in which mutated sequences of miR-145 were introduced. The amplified PCR fragments were then used as a template for a second PCR using primers N-cad --UTR-5.1 and N-cad --UTR-3.1. The final PCR production was confirmed by DNA sequencing. The PCR product was first cloned into a Taq-amplified (TA) vector (pTA2, Takara, Ostu, Shiga, Japan) and then subcloned into a pmirGLO miRNA target expression vector (Promega, San Lius Obispo, CA, USA) where Xba I and Sac I sites were introduced into the multiple cloning site. The pmirGLO vector is designed to quantitatively evaluate miRNA activity with firefly luciferase used as the primary reporter to monitor miRNA regulation and Renilla luciferase as a control reporter for normalization of gene expression.
Luciferase assay
Luciferase assays were carried out in both BGC-823 and SGC-7901 cells. Cells (1 Â 10 5 ) were plated in 12-well plates, 24 h before transfection. Thirty nanomoles of miR-145 precursor or miR-negative control and 30 ng pmirGLO-3 0 -UTR vector were co-transfected into cells using X-tremeGENE transfection reagent (Roche Applied Science). Renilla and firefly luciferase activities were measured with the Dual-Luciferase Reporter system (Promega) 24 h after transfection. Firefly luciferase activity was normalized to Renilla luciferase expression for each sample. Each experiment was performed in triplicate.
Western blot
Western blot was performed as described previously. 7 Briefly, protein was extracted from cells or tissues. Lysates were resolved by electrophoresis, transferred to nitrocellulose membranes and blotted with antibodies against actin and N-cadherin (1:500, Abcam, Cambridge, UK), E-cadherin (1:500, Abcam), MMP2 (1:500, Abcam) or MMP9 (1:1000, Abcam).
Immunohistochemistry
IHC was used to detect N-cadherin and Ki-67 in human gastric cancer tissues and in cell culture. For gastric cancer tissues, antigen retrieval (15 min) was applied before incubation with primary antibody. A total of 500 tumor cells chosen randomly in each case were counted and the percentage of positive tumor cells was evaluated.
For cell culture, the cells were grown on coated cover slips overnight before IHC staining.
Experimental metastasis assay SGC-7901 cells were transfected with lentivirus miR-145-expressing vector pEZX-miR145 (Genecopeia, Rockville, MD, USA), which has GFP as a marker protein. For the invasion and spontaneous metastasis assays in vivo, male NOD/SCID mice (age: 4 weeks) were injected into the left axillary fossa with 2 Â 10 6 cells plus normal medium. For the experimental metastasis assay, mice were injected with 2 Â 10 6 cells via the tail vein. GFP imaging of living mice was measured using a In-vivo Imaging System Kodak 2000 imager (Kodak). Six weeks post implantation, the animals were killed, and the tumor nodules and lungs of mice were harvested. Tumor volume (V) was calculated as V ¼ (a Â b 2 )/2 where a and b are the long and short axes of the tumor nodule, respectively. Histological analyses were used to detect distant metastasis in lungs. Metastases were first observed with a fluorescent microscope (Leica DMIRE2) in frozen sections within 2 h of specimen isolation, and then confirmed and quantified in paraffinembedded H&E sections. The metastatic cancer cells were further confirmed by immunostaining for CEA, a marker for gastroenterology adenocarcinoma. A portion of tumor tissues was used to extract total RNAs and proteins for RT --qPCR and western blot analysis.
Statistical analyses
Data are presented as median ± s.d. Differences were analyzed with Student's t-test between two groups or with one-way analysis of variance among three groups. For continuous data, the Mann --Whitney U-test was used for unpaired data and the Wilcoxon matched pairs test for paired data. The correlation between miR-145 level and N-cadherin protein expression or tumor size in human gastric cancers was calculated by Spearman's correlation. A P-value o0.05 was considered statistically significant.
